EUVIMEDEUVIMED entdecken
Open Access

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Chemotherapie-induzierte biologische Altersbeschleunigung und Lebenszeitfolgen bei Brustkrebsüberlebenden

Swarnavo Sarkar, Mina S Sedrak, Judith E Carroll, Clyde Schechter, Hyman B Muss, Jeanne S Mandelblatt

JAMA Network Open · 10.11.2026 · 9 (11) · e2643008

DOI: 10.1001/jamanetworkopen.2026.43008 ↗

Auf einen Blick

Das Simulationsmodell zeigte: Nach Anthrazyklintherapie gingen mehr verbleibende Lebensjahre verloren und die Nicht-Brustkrebs-Mortalität trat früher in den Vordergrund als erwartet. Der Effekt war bei jüngerer Diagnose stärker variabel.

Fragestellung

Wie groß ist das Spektrum lebenslanger Veränderungen durch beschleunigte Alterung nach Chemotherapie bei Brustkrebsüberlebenden?

Methode

Vergleichende Effektivitätsstudie mit etabliertem Brustkrebsmodell des Cancer Intervention and Surveillance Modeling Network; Simulationen für anthrazyklinbasierte vs. nichtanthrazyklinbasierte Schemata; Modellierung November 2025 bis April 2026.

Ergebnisse

Simulierte Population: 400 Millionen US-Amerikanerinnen mit Brustkrebs im Alter von 30 bis 79 Jahren. Anthrazyklinempfängerinnen verloren 9,4 (IQR 7,6-11,2) Lebensjahre; Nicht-Brustkrebs-Mortalität 16 (IQR 12-19) Jahre früher als erwartet. Die Differenz betrug median 7,6 (IQR 7,0-8,0) Jahre.

Schlussfolgerung der Autor:innen

In dem Simulationsmodell war eine stärkere Überlebenszeit nach Brustkrebs mit mehr zytotoxischen Schemata verbunden, aber auch mit einem höheren Potenzial für frühere Nicht-Brustkrebs-Mortalität durch Altersbeschleunigung.

Kernaussagen

  • Anthrazyklintherapie: 9,4 verbleibende Lebensjahre verloren
  • Nicht-Brustkrebs-Mortalität 16 Jahre früher als erwartet
  • Mehr zytotoxische Schemata: median 7,6 Jahre Differenz

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 10.11.2026. Verfasst von Swarnavo Sarkar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Aging, Antineoplastic Agents. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Growing evidence suggests some breast cancer survivors may experience accelerated aging (biological age in excess of chronological age) after receiving chemotherapy.

Objective

To quantify the range of lifetime changes in accelerated aging following chemotherapy. Design, Setting, and Participants This comparative effectiveness study used an established Cancer Intervention and Surveillance Modeling Network breast cancer model integrating biological aging with breast cancer epidemiology. Biological aging was modeled using data on distributions of postchemotherapy senescence measured by p16 INK4a levels, and the model assumed chemotherapy-induced senescence only affected non–breast cancer mortality. The simulated population included US women diagnosed with breast cancer at ages 30 to 79 years between 1990 and 2030, with follow-up until death. Two model simulations were run; the first assumed all women who developed breast cancer received anthracycline, and the second assumed all received nonanthracycline treatment. Modeling was conducted from November 2025 to April 2026. Results were validated by comparing model-predicted trends with findings from the Anthracycline for Early Breast Cancer (ABC) trials. Exposures More vs less cytotoxic chemotherapy, using exemplar anthracycline-based vs nonanthracycline regimens. Main Outcomes and Measures Lifetime outcomes included the age at which the risk of non–breast cancer mortality exceeded the risk of breast cancer mortality by chemotherapy regimen, posttreatment life-years, and all-cause mortality by age group at diagnosis and median senescence levels.

Results

The study included a simulated population of 400 million US women aged 30 to 79 years diagnosed with breast cancer. Breast cancer survivors who received anthracycline lost 9.4 (IQR, 7.6-11.2) years of remaining life years. Overall, among anthracycline recipients, the risk of non–breast cancer mortality was projected to exceed breast cancer mortality 16 (IQR, 12-19) years earlier than expected based on chronological age. There was heterogeneity in results, with greater variability for women diagnosed at younger vs older ages. Women receiving more vs less cytotoxic regimens were estimated to lose a median difference of 7.6 (IQR, 7.0-8.0) more years of life due to earlier ages at onset of aging-related diseases. The model closely replicated all-cause and 8-year breast cancer survival trends in the ABC trials. Conclusions and Relevance In this simulation model of chemotherapy-induced biological aging, increased breast cancer survival was seen with more (vs less) cytotoxic regimens, but this was paired with greater potential risk of earlier non–breast cancer mortality due to age acceleration. These results suggest the value of integrating knowledge about biological aging into survivorship care and could inform future research to address accelerated aging among breast cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCancer SurvivorsAgingAntineoplastic AgentsHumansFemaleMiddle AgedAgedAdultAnthracyclines

Substanzen

Antineoplastic AgentsAnthracyclines

Autor:innen und Institutionen

  • Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
  • Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles.
  • Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles.
  • Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, New York.
  • Department of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.
  • Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

Zitieren

APA

Sarkar, S., Sedrak, M. S., Carroll, J. E., Schechter, C., Muss, H. B., & Mandelblatt, J. S. (2026). Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Network Open, 9(11), e2643008. https://doi.org/10.1001/jamanetworkopen.2026.43008

Vancouver

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Network Open. 2026;9(11):e2643008. doi:10.1001/jamanetworkopen.2026.43008

BibTeX
@article{Sarkar2026,
  author = {Sarkar, Swarnavo and Sedrak, Mina S and Carroll, Judith E and Schechter, Clyde and Muss, Hyman B and Mandelblatt, Jeanne S},
  title = {Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {11},
  pages = {e2643008},
  doi = {10.1001/jamanetworkopen.2026.43008}
}
Kostenlos starten →